Market capitalization | $70.53m |
Enterprise Value | $61.37m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.63 |
P/S ratio (TTM) P/S ratio | 3.02 |
P/B ratio (TTM) P/B ratio | 7.53 |
Revenue growth (TTM) Revenue growth | 74.10% |
Revenue (TTM) Revenue | $23.33m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
5 Analysts have issued a electroCore, Inc. forecast:
5 Analysts have issued a electroCore, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 23 23 |
74%
74%
|
|
Gross Profit | 19 19 |
76%
76%
|
|
EBITDA | -12 -12 |
40%
40%
|
EBIT (Operating Income) EBIT | -13 -13 |
37%
37%
|
Net Profit | -13 -13 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
electroCore, Inc. is a commercial stage medical device company, which engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats, and Thomas J. Errico in September 2005 and is headquartered in Basking Ridge, NJ.
Head office | United States |
CEO | Daniel Goldberger |
Employees | 68 |
Founded | 2005 |
Website | www.electrocore.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.